Establishing Good Practices for Exposure–Response Analysis of Clinical Endpoints in Drug Development

This tutorial aims at promoting good practices for exposure–response (E‐R) analyses of clinical endpoints in drug development. The focus is on practical aspects of E‐R analyses to assist modeling scientists with a process of performing such analyses in a consistent manner across individuals and projects and tailored to typical clinical drug development decisions. This includes general considerations for planning, conducting, and visualizing E‐R analyses, and how these are linked to key questions.

• Publication year

  2015

• Venue

  CPT: Pharmacometrics & Systems Pharmacology

• Publication date

  2015-09-22

• Fields of study

  Mathematics, Medicine

• Identifiers
  DOI 10.1002/psp4.12015PMID 26535157PMCID 4625861
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• History and Perspectives

  2017cited by this paper
• Industry Perspective

  2017cited by this paper
• Key findings towards optimising adalimumab treatment: the concentration-effect curve.

  2015cited by this paper
• Concentration-response Model of Lopinavir/Ritonavir in HIV-1–infected Pediatric Patients

  2014cited by this paper
• Performance of Nonlinear Mixed Effects Models in the Presence of Informative Dropout

  2014cited by this paper
• Information contributed by meta-analysis in exposure–response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis

  2014cited by this paper
• Exposure–Response Modeling of Clinical End Points Using Latent Variable Indirect Response Models

  2014cited by this paper
• A Time to Event Tutorial for Pharmacometricians

  2013cited by this paper
• Comparisons of Analysis Methods for Proof-of-Concept Trials

  2013cited by this paper
• The Combination of Exposure‐Response and Case‐Control Analyses in Regulatory Decision Making

  2013cited by this paper
• Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance

  2013cited by this paper
• The Prevention and Treatment of Missing Data in Clinical Trials: An FDA Perspective on the Importance of Dealing With It

  2012cited by this paper
• Human Medicines Development and Evaluation Concept paper on extrapolation of efficacy and safety in medicine development

  2012cited by this paper
• Fundamentals of population pharmacokinetic modelling: validation methods.

  2012cited by this paper
• Guidelines for the Quality Control of Population Pharmacokinetic–Pharmacodynamic Analyses: an Industry Perspective

  2012cited by this paper
• Fundamentals of Population Pharmacokinetic Modelling

  2012cited by this paper
• Exposure–Response modeling of anti-depressant treatments: the confounding role of placebo effect

  2012cited by this paper
• Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions

  2011cited by this paper
• Combination of exposure-response and case-control analyses in regulatory decision making.

  2011cited by this paper
• Exposure response – getting the dose right

  2009cited by this paper
• Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s Disease

  2009cited by this paper
• Pharmacokinetic–Pharmacodynamic Modelling: History and Perspectives

  2006cited by this paper
• Population Pharmacokinetics III: Design, Analysis, and Application of Population Pharmacokinetic Studies

  2004cited by this paper
• Population Pharmacokinetics I: Background, Concepts, and Models

  2004cited by this paper
• Population Pharmacokinetics II: Estimation Methods

  2004cited by this paper
• A Joint Model for Nonlinear Longitudinal Data with Informative Dropout

  2003cited by this paper
• Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.

  1997cited by this paper

• When ‘Dirty’ Drugs Become Useful: Peptide-Guided Exposure Engineering for the Repurposing of Cancer Drugs

  2026cites this paper
• Population Pharmacokinetic and Exposure‐Efficacy Analyses of Valbenazine in Patients with Huntington's Disease: Supporting Dose Selection for Chorea Management

  2025cites this paper
• Exposure‐Response Analysis for Time‐to‐Event Data in the Presence of Adaptive Dosing: Efficient Approaches and Pitfalls

  2025cites this paper
• Exposure–Response Modeling of Monthly Migraine Days for Efficacy of Atogepant in Patients With Episodic or Chronic Migraine

  2025cites this paper
• Model‐Informed Drug Development Supports Full Approval of Ibuprofen Injection in Chinese Pediatric Patients With Fever or Pain

  2025cites this paper
• Endpoint Exposure‐Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials

  2025cites this paper
• Optimizing Dosing Strategies in Cell Therapy With Machine Learning and Exposure‐Response Integration

  2025cites this paper
• A Perspective on the Use of Poisson Versus Logistic Regression in Exposure–Response Analysis: Insights and Considerations

  2025cites this paper
• Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR‐Mutated Advanced NSCLC

  2025cites this paper
• Exposure‐Response Relationships for Axatilimab in Patients with Chronic Graft‐Versus‐Host Disease

  2025cites this paper
• Modeling exposure-driven adverse events of EGFR TKIs in the treatment of patients with non-small cell lung cancer

  2025cites this paper
• Machine Learning Prediction and Validation of Plasma Concentration–Time Profiles

  2025cites this paper
• Implementing exposure limits for players in contact team sports: review of principles and practices

  2025cites this paper
• Impact of using time-averaged exposure metrics on binary endpoints in exposure-response analyses

  2025cites this paper
• Estimands for Early‐Phase Dose Optimization Trials in Oncology

  2025cites this paper
• Optimizing First‐Line Therapeutics in Non‐Small Cell Lung Cancer: Insights From Joint Modeling and Large‐Scale Data Analysis

  2024cites this paper
• Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region

  2024cites this paper
• A Practical In Silico Method for Predicting Compound Brain Concentration-Time Profiles: Combination of PK Modeling and Machine Learning.

  2024cites this paper
• Inter‐regional pharmacokinetics and exposure–response analyses of belimumab in patients with system lupus erythematosus

  2024cites this paper
• Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs

  2024cites this paper
• Integrated Population Exposure–Response of Dolutegravir in HIV‐1 Supports Bridging of Clinical Response Influenced by Relevant Intrinsic and Extrinsic Patient Characteristics

  2024cites this paper
• Toward Personalized Salbutamol Therapy: Validating Virtual Patient-Derived Population Pharmacokinetic Model with Real-World Data

  2024cites this paper
• Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

  2024cites this paper
• In Silico Clinical Trials: Is It Possible?

  2024cites this paper
• Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

  2023cites this paper
• Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature

  2023cites this paper
• Exposure-response analysis of the efficacy and safety of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with or without diabetic kidney disease.

  2023cites this paper
• Machine Learning‐Based Quantification of Patient Factors Impacting Remission in Patients With Ulcerative Colitis: Insights from Etrolizumab Phase III Clinical Trials

  2023cites this paper
• Skipping a pillar does not make for strong foundations: Pharmacokinetic‐pharmacodynamic reasoning behind the shape of dose–response relationships in oncology

  2023cites this paper
• Mechanism-based pharmacokinetic and pharmacodynamic modeling for bispecific antibodies: challenges and opportunities

  2023cites this paper
• Garetosmab in Fibrodysplasia Ossificans Progressiva: Clinical Pharmacology Results from the Phase 2 LUMINA‐1 Trial

  2023cites this paper
• Quantitative Assessment of Ribociclib Exposure–Response Relationship to Justify Dose Regimen in Patients with Advanced Breast Cancer

  2023cites this paper
• Modeling of Proliferating CD4 and CD8 T‐Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma

  2023cites this paper
• Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

  2023cites this paper
• Machine Learning for Exposure-Response Analysis: Methodological Considerations and Confirmation of Their Importance via Computational Experimentations

  2023cites this paper
• Prediction of Compound Plasma Concentration–Time Profiles in Mice Using Random Forest

  2023cites this paper
• Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis

  2023cites this paper
• Exposure‐Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product

  2022cites this paper
• Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer

  2022cites this paper
• Bayesian Complex Innovative Trial Designs (CIDs) and Their Use in Drug Development for Rare Disease

  2022cites this paper
• Applying interpretable machine learning workflow to evaluate exposure–response relationships for large‐molecule oncology drugs

  2022cites this paper
• Pimavanserin Exposure-Response Analyses in Patients With Schizophrenia

  2022cites this paper
• Dose/exposure–response modeling in dose titration trials: Overcoming the titration paradox

  2022cites this paper
• Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis

  2022cites this paper
• Improving categorical endpoint longitudinal exposure–response modeling through the joint modeling with a related endpoint

  2021cites this paper
• Model-informed drug development and discovery: an overview of current practices

  2021cites this paper
• Recurrent events modelling of haemophilia bleeding events

  2021cites this paper
• V2ACHER: Visualization of complex trial data in pharmacometric analyses with covariates

  2021influential citation
• Population pharmacokinetic and exposure–response analysis of apremilast in Japanese subjects with moderate to severe psoriasis

  2021cites this paper
• Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes

  2021cites this paper
• NONCLINICAL, CLINICAL, AND MODEL‐INFORMED DRUG DEVELOPMENT

  2021cites this paper
• Translation of Pharmacodynamic Biomarkers of Antibiotic Efficacy in Specific Populations to Optimize Doses

  2021cites this paper
• Applying Beta Distribution in Analyzing Bounded Outcome Score Data

  2020cites this paper
• Demonstrating Contribution of Components of Fixed-Dose Drug Combinations Through Longitudinal Exposure-Response Analysis

  2020cites this paper
• Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV

  2020cites this paper
• Population pharmacokinetic and exposure-response analyses of d-amphetamine after administration of lisdexamfetamine dimesylate in Japanese pediatric ADHD patients.

  2020cites this paper
• Facilitating Longitudinal Exposure-Response Modeling of a Composite Endpoint Using the Joint Modeling of Sparsely and Frequently Collected Subcomponents

  2020cites this paper
• Application of Beta-Distribution and Combined Uniform and Binomial Methods in Longitudinal Modeling of Bounded Outcome Score Data

  2020cites this paper
• Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care.

  2020cites this paper
• Exposure‐Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy

  2020cites this paper
• Challenges and Opportunities With Oncology Drug Development in China

  2019cites this paper
• Consideration of a Credibility Assessment Framework in Model‐Informed Drug Development: Potential Application to Physiologically‐Based Pharmacokinetic Modeling and Simulation

  2019cites this paper
• Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response Models

  2019cites this paper
• Use of dose–exposure–response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis

  2019cites this paper
• Transitioning from Preclinical to Clinical Drug Development

  2019cites this paper
• Exposure–response analysis of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukaemia and comparison with standard of care chemotherapy

  2019cites this paper
• Power Determination During Drug Development: Is Optimizing the Sample Size Based on Exposure‐Response Analyses Underutilized?

  2019cites this paper
• Generating Model Integrated Evidence for Generic Drug Development and Assessment

  2019cites this paper
• Model‐Informed Drug Discovery and Development: Current Industry Good Practice and Regulatory Expectations and Future Perspectives

  2019cites this paper
• Feasibility of Exposure-Response Analyses for Clinical Dose-Ranging Studies of Drug Combinations

  2018cites this paper
• Exposure- and Dose-response Analyses in Dose Selection and Labeling of FDA-approved Biologics.

  2018cites this paper
• A comprehensive evaluation of exposure–response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis

  2018cites this paper
• Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure–response modeling of Mayo scores for golimumab in patients with ulcerative colitis

  2018cites this paper
• Bayesian dose‐finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology

  2018cites this paper
• Joint longitudinal model development: application to exposure–response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab

  2018cites this paper
• Exposure‐Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid Arthritis

  2018cites this paper
• Evaluating cardiac risk: exposure response analysis in early clinical drug development

  2018cites this paper
• Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes

  2018cites this paper
• Role of Clinical Pharmacokinetics Studies in Contemporary Oncology Drug Development

  2018cites this paper
• A retrospective examination of the US Food and Drug Administration’s clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring

  2017cites this paper
• Commentary on the MID3 Good Practices Paper

  2017cites this paper
• Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients

  2017cites this paper
• Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS).

  2017cites this paper
• Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn’s disease

  2017cites this paper
• Landmark and longitudinal exposure–response analyses in drug development

  2017cites this paper
• Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors

  2017cites this paper
• Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation

  2016cites this paper
• Pharmacological considerations for predicting PK/PD at the site of action for therapeutic proteins.

  2016cites this paper
• Pharmacokinetic-Pharmacodynamic Modelling of Fixed- Dose Combinations: A Regulatory Perspective

  year unknowninfluential citation